Related Experiment Video

Updated: Aug 6, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Intradialytic Kinetics of Cardiac Biomarkers During High-Flux Hemodialysis and Post-Dilution Hemodiafiltration: A

Caroline Liboriussen Drivsholm1,2, Louis Nygaard1,3, Gertrud Dam-Dalgeir4

  • 1Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark.

Kidney360
|July 20, 2026
PubMed

Insights

Hemodiafiltration significantly reduces cardiac biomarkers like troponin I/T and NT-proBNP, unlike hemodialysis. Understanding these changes is crucial for accurate cardiac biomarker interpretation in dialysis patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Biochemistry

Background:

  • Limited data exist on hemodialysis effects on cardiac biomarker concentrations.
  • Cardiac biomarkers such as high-sensitivity troponin I/T and NT-proBNP are commonly used in clinical practice.

Purpose of the Study:

  • To investigate changes in cardiac biomarker concentrations during and after hemodialysis and hemodiafiltration.
  • To compare the impact of hemodialysis versus hemodiafiltration on these biomarkers.

Main Methods:

  • A randomized crossover study involving 23 stable dialysis patients.
  • Patients underwent both high-flux hemodialysis and post-dilution hemodiafiltration.
  • Blood samples were collected at multiple time points before, during, and after dialysis sessions.

Main Results:

  • Hemodiafiltration significantly reduced high-sensitivity troponin I and T levels, while hemodialysis did not.
  • Both hemodialysis and hemodiafiltration reduced N-terminal pro-B-type natriuretic peptide.
  • Cardiac biomarker concentrations were significantly lower after hemodiafiltration compared to hemodialysis.

Conclusions:

  • Hemodiafiltration effectively reduces cardiac biomarkers, including troponin I/T and NT-proBNP, in dialysis patients.
  • Hemodialysis primarily reduces NT-proBNP.
  • Dialysis modality influences cardiac biomarker levels, necessitating consideration of the time since the last dialysis session for accurate interpretation.
Abstract

Related Concept Videos

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...